Eastern Cooperative Oncology Group

东部肿瘤合作组

基本信息

批准号：
7425432
负责人：
ARLENE ANN FORASTIERE
金额：
$ 27.96万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1978
资助国家：
美国
起止时间：
1978-06-01 至 2010-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7425432
关键词：
ABT-510 ABT-751 AIDS Malignancy Consortium Accounting Acquired Immunodeficiency Syndrome Acute Promyelocytic Leukemia Acute leukemia Adenovirus Vector Adenoviruses Adherence Adjuvant Adult Advanced Malignant Neoplasm African American Allogenic American American Society of Clinical Oncology American Society of Hematology Aminocamptothecin Angiogenesis Inhibitors Anthracycline Antibiotics Anthracyclines Antibodies Antigens Apoptosis Apoptotic Area Arsenic Trioxide Astrocytoma Atrasentan Attention Autologous Autologous Bone Marrow Transplantation Autologous Transplantation Award Awareness Axilla Azacitidine Baltimore Belief Biochemical Biological Markers Biology Biopsy Bladder Blood Brain Neoplasms Breast Breast Cancer Cell CCI-779 CEP7055 CSF3 gene Calcitriol Cancer Biology Cancer Cell Growth Regulation Cancer Center Cancer Patient Cancer Research Project Cancer Vaccines Cancer and Leukemia Group B Cancer cell line Carboplatin Cardiac Carmustine Catchment Area Cell Cycle Cell Cycle Regulation Cell Differentiation process Cell Line Cell Proliferation Cells Cellular biology Censuses Central Nervous System Lymphoma Cervical Cervical Cancer Screening Chairperson Chemoprevention Chemotherapy-Oncologic Procedure Chest Chronic Lymphocytic Leukemia Cisplatin Cisplatin/Irinotecan Cisplatin/Paclitaxel Clinic Clinical Clinical Data Clinical Investigator Clinical Protocols Clinical Research Clinical Research Protocols Clinical Trials Collaborations Colon Carcinoma Commit Committee Members Communities Community Clinical Oncology Program Community Health Comprehensive Cancer Center Consent Forms Continuous Infusion Contracts Correlative Study Coxibs Cranial Irradiation Cyclophosphamide Cyclophosphamide/Fludarabine Cyclophosphamide/Thiotepa Cyclosporine Cyclosporins Cytokine Gene Cytotoxic agent DAP kinase DHA-Paclitaxel DNA Methyltransferase Inhibitor DNA Repair Gene DNA Vaccines Daily Data Data Quality Databases Detection Detox Development Dexamethasone Diagnosis Diet and Nutrition Differentiation Inducer Diffuse Large-Cell Lymphoma Discipline of Nuclear Medicine Disease Disorder by Site Docetaxel/Doxorubicin Docetaxel/Estramustine Docetaxel/Exisulind Doctor of Pharmacy Doctor of Philosophy Dose Down-Regulation Doxorubicin Drug Delivery Systems Drug Interactions Drug Kinetics Dysmyelopoietic Syndromes ERBB2 gene Early Diagnosis Early treatment Eastern Cooperative Oncology Group Education Elements Eligibility Determination Endocrine Endothelin Receptor Antagonist Enrollment Ensure Enzymes Epidemiology Epidermal Growth Factor Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epigenetic Process Equipment and supply inventories Esophageal Esophageal Adenocarcinoma Estramustine European Evaluation Excision External Beam Radiation Therapy Faculty Family member Feasibility Studies Filgrastim Florida Follow-Up Studies Fostering Foundations Functional disorder Funding Gender Gene Mutation Gene-Modified Genes Genetic Genitourinary system Germ-Line Mutation Gleevec Gliadel Glioblastoma Glioma Goals Grant Granulocyte-Macrophage Colony-Stimulating Factor Growth Growth Factor Head Head and Neck Cancer Head and Neck Surgery Head and neck structure Health Educators Hematologic Neoplasms Hematopoietic Histologic Histone Acetylation Histone Deacetylase Histone Deacetylase Inhibitor Hodgkin Disease Hormone Responsive Hormones Hot flushes Hour Human Herpesvirus 4 Human Papilloma Virus Vaccine Human Papillomavirus Human Resources Human papillomavirus 16 Hydrocortisone/Ketoconazole Hypermethylation Image Immune Immune response Immunology Immunotherapy Immunotoxins In Vitro Indolent Infection Inflammatory Informed Consent Injury Institutes Institution Interferon Type II Interferons Intestinal Cancer Intestines Intravenous Investigation Investigational Drugs Isotretinoin Journals Laboratories Laboratory Research Latino Lead Leadership Library Protocol Life Liposomal Doxorubicin Liposomes Lung Lymph node excision Lymphoma Lymphoproliferative Disorders MCF7 cell MS-275 MabCampath Magnetic Resonance Imaging Maintenance Malignant Glioma Malignant Neoplasms Malignant lymphoid neoplasm Malignant neoplasm of brain Malignant neoplasm of cervix uteri Malignant neoplasm of esophagus Malignant neoplasm of larynx Malignant neoplasm of lung Malignant neoplasm of nasopharynx Malignant neoplasm of pancreas Malignant neoplasm of prostate Malignant neoplasm of urinary bladder Mammary Neoplasms Marrow Maryland Matrix Metalloproteinase Inhibitor Mediating Medical Faculty Medical Oncologist Medical Oncology Medicine Menopausal hot flushes Methods Methotrexate Methylation Methyltransferase Minority Minority Groups Mission Mitosis Modality Modeling Molecular Molecular Biology Monitor Monoclonal Antibodies Mosses Multiple Hamartoma Syndrome Multiple Myeloma Mutate Mutation NF-kappa B Negative Lymph Node Neoadjuvant Therapy Neoplasm Metastasis Netherlands Neuraxis Neurology New Agents New England Newly Diagnosed Non-Hodgkin&apos s Lymphoma Non-Small-Cell Lung Carcinoma North Central Cancer Treatment Group Numbers Nurses Nursing Research Nursing Staff O(6)-Methylguanine-DNA Methyltransferase Oblimersen Octreotide Oligonucleotides Oncologic Nursing Oncology Nurse Online Systems Operative Surgical Procedures Oral cavity Oregon Organ Preservation Oropharyngeal Otolaryngology Outcome PTEN gene Paclitaxel Pancreas Paper Participant Pathologic Pathologist Pathology Pathway interactions Patients Pattern Pediatric Oncology Peripheral Peripheral Blood Stem Cell Pharmaceutical Preparations Pharmacists Pharmacodynamics Pharmacogenetics Pharmacogenomics Pharmacology Pharmacy facility Phase Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phenylbutyrates Physicians Physics Pilot Projects Plasma Policy Research Polyamines Polymerase Chain Reaction Population Positioning Attribute Positive Lymph Node Positron-Emission Tomography Pre-Clinical Model Premenopause Preparation Prevention Prevention program Primary Neoplasm Principal Investigator Printing Procedures Process Prodrugs Prognostic Factor Prostate Protein Overexpression Protocol Agent Protocols documentation Public Health Schools Pulmonary Pathology Quality of life RSR-13 Race Radiation Radiation Oncologist Radiation Oncology Radiation enhancer Radiation therapy Radical Prostatectomy Radiology Specialty Randomized Range Rate Rattus Recruitment Activity Recurrence Refractory Refractory Disease Regulator Genes Relapse Renal Cell Carcinoma Reporting Reproduction spores Research Research Ethics Committees Research Infrastructure Research Personnel Resected Resistance Resources Reverse Transcriptase Polymerase Chain Reaction Review Committee Risk Roche brand of trastuzumab Role Running Safety Schedule Science Screening for Prostate Cancer Screening procedure Secure Sentinel Series Serum Serum Markers Signal Transduction Inhibitor Sirolimus Site Sodium Solid Neoplasm Source Southwest Oncology Group Specialist Spermine Spouses Squamous cell carcinoma Staging Staining method Stains Standards of Weights and Measures Stem cell transplant Sterically Stabilized Liposome Study models Supratentorial Suramin Surgical Oncologist Surrogate Markers System Systemic Therapy T-Cell Activation T-Lymphocyte TP protocol TP53 gene Tamoxifen Target Populations Taxane Compound Techniques Testing Texas Thalidomide Therapeutic Therapy Clinical Trials Thiotepa Thoracic Surgical Procedures Thymoma Time Tissue Banks Tissues Toxic effect Transcript Translating Translational Research Transplantation Trastuzumab Treatment Protocols Tretinoin Tumor Markers Tumor Suppressor Genes Tumor Suppressor Proteins Tyrosine Kinase Inhibitor United States National Institutes of Health Universities Unresectable Update Urology Vaccine Therapy Vaccines Valproic Acid Variant Viral Virus Vorinostat Voting Week Whole Cell Vaccine Wisconsin Woman Work Writing Yang Zoledronic Acid abstracting analog angiogenesis antiangiogenesis therapy antibody-dependent cell cytotoxicity base benzoylphenylurea bevacizumab bleomycin/dacarbazine/doxorubicin/vinblastine protocol bone burden of illness caN protocol cancer cell cancer education cancer prevention cancer research center director carcinogenesis celecoxib chemotherapeutic agent chemotherapy cigarette smoking clinical application clinical efficacy concept cytotoxic data management day design disorder risk docetaxel drug development experience fludarabine forging gemcitabine gene therapy gliosarcoma graft vs host disease hydroxyurea immunogenicity improved in vivo inhibitor/antagonist innovation interdisciplinary approach interest irradiation leukemia leukemia/lymphoma lymph nodes mTOR Inhibitor malignant breast neoplasm malignant oropharynx neoplasm member men meningioma mimetics multidisciplinary neuro-oncology neuropathology neurosurgery novel novel strategies oncology organizational structure outcome forecast patient oriented phenylbutyrate pill pilot trial pre-clinical programs promoter protocol development purge receptor receptor expression research facility response rituximab taxane trial comparing tumor tumor immunology tumor necrosis factor receptor superfamily, member 10b protein, mouse urinary vaccine evaluation viral DNA virology

项目摘要

DESCRIPTION (provided by applicant): Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative science piloted at Johns Hopkins to the Group for further development. In conjunction with this, our faculty serves in leadership roles as study chairs and laboratory co-chairs, disease and modality-oriented committee chairs. The specific aims are: 1) to continue to provide scientific leadership in the disease-oriented committees: Breast, Thoracic, Head and Neck, Genitourinary, Brain Tumor Working Group, Lymphoma, Leukemia; 2) to expand our involvement to the disease and modality committees: Gastro-intestinal, Myeloma, Pharmacology and Drug Development; 3) to bring translational research correlates, cell biology and molecular biology into clinical protocols for all stages of disease; 4) to expand our accrual and maintain excellence in data quality. We expect to accomplish these goals through the mission of the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins: to provide a multidisciplinary approach to the study of cancer that will result in improved means for prevention, diagnosis and treatment. The Center has achieved excellence in translational research with the awarding of six SPORE grants (lymphoma, G-I cancer, prostate, breast, lung, head and neck). In addition, we perform early clinical trials of new drugs (NCI phase I contract since 1982) and hold a contract for Early Therapeutics Development with Phase II Emphasis. These grants allow the development of novel phase II and phase Ill trial concepts which our faculty bring to ECOG with appropriate laboratory science correlative studies. Our accrual and committee involvement is expected to continue to grow because of expanding clinical programs and faculty made possible with a new Cancer Center facility and research buildings occupied since late 2000.

描述（由申请人提供）：约翰·霍普金斯大学自 1955 年以来一直是 ECOG 的成员。我们的主要目标是将约翰·霍普金斯大学试点的创新临床研究方案和实验室相关科学引入该集团以供进一步发展。与此同时，我们的教师担任研究主席和实验室联合主席、疾病和模式导向委员会主席等领导角色。具体目标是： 1) 继续在以疾病为导向的委员会中提供科学领导：乳腺、胸腔、头颈、泌尿生殖、脑肿瘤工作组、淋巴瘤、白血病； 2) 将我们的参与范围扩大到疾病和模式委员会：胃肠、骨髓瘤、药理学和药物开发； 3) 将相关转化研究、细胞生物学和分子生物学纳入疾病各个阶段的临床方案； 4) 扩大我们的应计收益并保持卓越的数据质量。我们期望通过约翰霍普金斯大学悉尼金梅尔综合癌症中心的使命来实现这些目标：提供多学科方法来研究癌症，从而改善预防、诊断和治疗的手段。该中心在转化研究方面取得了卓越成就，获得了六项 SPORE 资助（淋巴瘤、G-I 癌、前列腺癌、乳腺癌、肺癌、头颈癌）。此外，我们还开展新药的早期临床试验（自 1982 年起与 NCI 一期合同），并持有以二期为重点的早期治疗药物开发合同。这些赠款允许开发新颖的 II 期和 III 期试验概念，我们的教师将这些概念通过适当的实验室科学相关研究带到 ECOG。由于自 2000 年底以来新的癌症中心设施和研究大楼投入使用，临床项目和教职人员的扩大成为可能，因此我们的应计费用和委员会参与预计将继续增长。